Premium
Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.
Author(s) -
Harris AL,
Potter C,
Bunch C,
Boutagy J,
Harvey DJ,
GrahameSmith DG
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb01005.x
Subject(s) - pharmacokinetics , pharmacology , bolus (digestion) , intravenous bolus , plasma clearance , chemistry , cytosine , bioassay , plasma concentration , half life , medicine , biology , biochemistry , dna , genetics
1 The pharmacokinetics of cytosine arabinoside were studied after a single i.v. bolus of 2 mg/kg ara‐C in patients with newly diagnosed untreated AML, using a bioassay and GC‐MS method to measure the plasma concentrations. 2 Most patients showed a bi‐ or tri‐phasic decline in plasma concentrations with time. Plasma clearance was 3.9 to 18.1 l/min as measured by the GC‐MS method, and terminal half‐lives varied from 7‐ 107 min. 3 There was poor correlation of the GC‐MS assay with the bioassay, probably because the latter was interfered with by the release of endogenous nucleosides from blasts after after ara‐C. 4 Plasma concentrations were measured by GC‐MS during continuous infusions in 14 patients. Plasma clearances were much lower than after a bolus, 0.39 to 5.25 l/min. 5 There was no correlation of response (remission or fall in peripheral blast count) with exposure to ara‐C calculated from infusion dose, clearance and duration of infusion. 6 This study shows that ara‐C pharmacokinetics varies markedly from patient to patient and that there is a wide range in the plasma concentrations associated with therapeutic response.